BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Amgen Europe B.V. submitted on 7 May 2001 applications for Marketing Authorisation 
to the European Agency for the Evaluation of Medicinal Products (EMEA) for Neulasta, in 
accordance with the centralised procedure falling within the scope of Part A of the Annex to Council 
Regulation No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur:  Dr. F. Rotblat 
Co-Rapporteur:  Dr. B. van Zwieten-Boot 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 22 May 2001. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on  30  July 
2001. The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 2 
August 2001. 
During  the  meeting  on  18-20  September  2001  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 20 September 2001. 
During the meeting on 18-20 September 2001 the CPMP agreed that there was no need for an 
inspection of the manufacturing sites for Pegfilgrastrim. 
The company submitted the responses to the CPMP consolidated List of Questions on 18 March 
2002. 
The Rapporteur circulated the response Assessment Report on the company’s responses to the 
List of Questions to all CPMP members on 25 April 2002. 
The  company  submitted  answers  to  outstanding  quality  questions  on  16  May  2002.  The 
Rapporteur circulated an Addendum to the Response Assessment Report to all CPMP members 
on 17 May 2002. 
During the meeting on 28 – 30 May 2002 the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Neulasta on 30 May 2002. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 22 August 2002. 
1/1 
   EMEA 2004 
 
 
 
 
 
 
 
 
 
